{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"15","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Kaplan and Meier product limit methods will be used to estimate the TTNT with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)","id":"OG000","title":"Tivantinib Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From registration on trial to next treatment or death due to any cause, whichever comes first","title":"Time to Next Treatment (TTNT)","type":"SECONDARY","unitOfMeasure":"number of months"}